Skip to main content

Advertisement

Log in

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

  • PHASE I STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose This phase I trial assessed the safety, dose limiting toxicity (DLT) and pharmacodynamics of PX-12 in adult patients with advanced refractory cancers. Methods PX-12 was administered to sequential cohorts as a 72-h infusion utilizing a portable infusion pump on days 1, 2, and 3 of a 21-day cycle at a starting dose level of 300 mg/m2/day and escalating dose levels till DLT was observed. Plasma thioredoxin (Trx-1), vascular endothelial growth factor (VEGF) and FGF-2 (fibroblast growth factor) levels were measured predose and during infusion of PX-12. Results Patients (n = 14) were enrolled to the following dose cohorts, 300 mg/m2 (n = 3), 400 mg/m2 (n = 10) and 500 mg/m2 (n = 1). Common grade 1/2 toxicities included fatigue, taste alteration and odor caused by expired drug metabolite. DLTs were one episode each of grade 3 hypoxia at the 400 mg/m2 and grade 3 reversible pneumonitis at the 500 mg/m2 dose levels. Best response was stable disease in a patient with rectal cancer. Predose Trx-1 levels (n = 12) ranged from 5.1 to 30.0 ng/mL (median 12.6 ng/mL). Conclusion PX-12 administered at 400 mg/m2/day by 72-hour infusion appears safe and tolerable. Inhibition of thioredoxin is a strategy worth evaluation with next generation of inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Powis G, Kirkpatrick DL (2007) Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7:392–7

    Article  CAS  PubMed  Google Scholar 

  2. Kontou M, Will RD, Adelfalk C et al (2004) Thioredoxin, a regulator of gene expression. Oncogene 23:2146–52

    Article  CAS  PubMed  Google Scholar 

  3. Grogan T, Fenoglio-Priser C, Zaheb R et al (2000) Overexpression of thioredoxin, a putative oncogene, in gastric carcinoma with associated change in proliferation and apoptosis. J Pathol 31:475–81

    CAS  Google Scholar 

  4. Nakamura H, Bai J, Nishinaka Y et al (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53–60

    CAS  PubMed  Google Scholar 

  5. Raffel J, Bhattacharyya AK, Cui H et al (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142:46–51

    Article  CAS  PubMed  Google Scholar 

  6. Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239–45

    Article  CAS  PubMed  Google Scholar 

  7. Welsh S, Bellamy WT, Briehl MM et al (2002) The recox protein thioredoxin-1 is necessary for the hypoxia dependent increase in HIF-1a and results in increased vascular endothelial growth factor formation by cancer cells and enhanced tumor angiogenesis. Cancer Research 62:5089–95

    CAS  PubMed  Google Scholar 

  8. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71–103

    Article  CAS  PubMed  Google Scholar 

  9. Kirkpatrick D, Kuperus M, Dowdeswell M et al (1998) Mechanism of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55:987–94

    Article  CAS  PubMed  Google Scholar 

  10. Ramanathan RK, Kirkpatrick DL, Belani CP et al (2007) A phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13:2109–14

    Article  CAS  PubMed  Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–16

    Article  CAS  PubMed  Google Scholar 

  12. Kirkpatrick DL, Hiscox A, Boice M, et al (2008) Screening plasma thioredoxin (Trx-1) to potentially guide clinical development of the Trx-1 inhibitor PX-12. EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”, Geneva, Switzerland, abstr 108

  13. Ramanathan RK, Abbruzzese J, Dragovich T et al (2011) A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67:503–509

    Article  CAS  PubMed  Google Scholar 

  14. Ramanathan RK, Dragovich T, Richards D, et al (2009) Results from phase Ib studies of PX12, a thioredoxin inhibitor in patients with advanced solid malignancies. J Clin Oncol 27:15 s (suppl) abstr 2571

    Google Scholar 

  15. Molina M, Camps C, Peñas R et al (2007). Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small cell lung cancer (NSCLC) patients (p). J Clin Oncol. 25:18S (Suppl), abstr 7628

  16. Callister ME, Burke–Gaffney A, Quinlan GJ et al (2006) Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61:521–527

    Article  CAS  PubMed  Google Scholar 

  17. Abdiu A, Nakamura H, Sahaf B et al (2000) Thioreodoxin blood level increases after servere burn injury. Antioxid Redox Signal 2:707–16

    Article  CAS  PubMed  Google Scholar 

  18. Leaver SK, MacCallum NS, Pingle V et al (2010) Increased plasma thioredoxin levels in patients with sepsis: Positive association with macrophage migration inhibitory factor. Intensive Care Med 36:336–41

    Article  CAS  PubMed  Google Scholar 

  19. Jikimoto T, Nishikubo Y, Koshiba M et al (2002) Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 38:765–72

    Article  CAS  PubMed  Google Scholar 

  20. Jekell A, Hossain A, Alehagen U et al (2004) Elevated circulating levels of thioredoxin and satress in chronic heart failure. Eur J Heart Fail 6:883–90

    CAS  PubMed  Google Scholar 

  21. Takahashi K, Chin K, Nakamura H et al (2008) Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 10:715–26

    Article  CAS  PubMed  Google Scholar 

  22. Marumoto M, Suzuki S, Hosono A et al (2009) Changes in thioredoxin concentrations: an observation in an ultra-marathon race. Environ Heatlth Prev Med 15:129–34

    Article  Google Scholar 

  23. Jantus-Lewintre E, Sanmartin E, Sirera R, et al (2011) Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer Apr 7. [Epub ahead of print]

  24. An SJ, Huang YS, Chen ZH, et al (2011) Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol Apr 3. [Epub ahead of print]

  25. Tolcher A, Papadopoulos K, Patniak A et al (2010) Preliminary Results of a Dose Escalation Study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) In Patients With Advanced Malignancies. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. November 16–19, Berlin, Germany. Abstr 381

  26. Fu JN, Li J, Tan Q et al (2011) Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Invest New Drugs 29:627–636

    Article  CAS  PubMed  Google Scholar 

  27. Koh MY, Spivak-Kroizman TR, Powis G (2010) HIF-1alpha and cancer therapy. Recent Results Cancer Res 180:15–34

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Nina Cantafio for editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ramesh K. Ramanathan.

Additional information

Sponsor: Oncothyreon Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramanathan, R.K., Stephenson, J.J., Weiss, G.J. et al. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs 30, 1591–1596 (2012). https://doi.org/10.1007/s10637-011-9739-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9739-9

Keywords

Navigation